ESS505 Pre-hysterectomy Protocol

This study has been completed.
Information provided by (Responsible Party):
Bayer Identifier:
First received: August 7, 2012
Last updated: April 2, 2014
Last verified: April 2014
This study has been designed to evaluate an investigational model of the Essure System for Permanent Birth Control. The investigational device is designed to offer all the advantages of the currently approved device. In addition, the investigational device offers immediate, permanent contraception without a three-month waiting period or 90-day confirmation test. This study has been designed to evaluate the effectiveness of the investigational device in causing tubal occlusion from insert placement through three months of wearing.

Condition Intervention
Device: ESS505 (BAY1454033)
Device: ESS305 (Essure, BAY1454032)
Device: ESS505-A (Essure, BAY1454033)

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: ESS505 Pre-hysterectomy Protocol: Safety and Short Term Effectiveness Study

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Ability of the insert to occlude the fallopian tube [ Time Frame: 0-3 months ] [ Designated as safety issue: No ]

Enrollment: 66
Study Start Date: July 2012
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Investigational (ESS505) / Control Device (ESS305) Device: ESS505 (BAY1454033) Device: ESS305 (Essure, BAY1454032)
Experimental: Investigational (ESS505-A) Device: ESS505 (BAY1454033) Device: ESS505-A (Essure, BAY1454033)

Detailed Description:

This study has previously been posted by Conceptus, Inc. (US).

After acquiring Conceptus, Inc., Bayer HealthCare AG (Germany) is the sponsor of the trial.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects who are scheduled to undergo a Laparoscopically Assisted Vaginal Hysterectomy (LAVH), Total Abdominal Hysterectomy (TAH), Total Vaginal Hysterectomy (TVH), Total Laparoscopic Hysterectomy (TLH) with Bilateral Total Salpingectomy or Bilateral Salpingo-oophorectomy (BSO), or Laparoscopic Supracervical Hysterectomy (LSH)
  • Subjects who are 18 years of age and older
  • Subjects who are able and willing to provide written informed consent
  • Subjects who agree to use a contraceptive method following Essure placement until the hysterectomy procedure

Exclusion Criteria:

  • Subjects with bilateral proximal tubal occlusion
  • Subjects who have undergone fallopian tube sterilization
  • Subjects with known endometrial or myometrial pathology which is likely to prevent access to the fallopian tube ostia
  • Subjects who are post-menopausal
  • Subjects with pelvic inflammatory disease (PID)
  • Subjects with gynecologic malignancy
  • Pregnancy or suspected pregnancy
  • Delivery or termination of a pregnancy less than 6 weeks before Essure micro-insert placement
  • Known allergy to contrast media
  • Any general health condition that may represent, in the opinion of the Investigator, an increased potential risk associated with participation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01664052

Canada, Saskatchewan
Regina, Saskatchewan, Canada, S4P 0W5
Chihuahua, Mexico, 31350
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Bayer Identifier: NCT01664052     History of Changes
Other Study ID Numbers: 17035  ESS505-002 
Study First Received: August 7, 2012
Last Updated: April 2, 2014
Health Authority: Canada: Health Canada
Mexico: Federal Commission for Sanitary Risks Protection processed this record on April 27, 2016